The new fund invests in the 45 pharmaceutical, biotechnology and medical device companies that comprise the AMIDEX eMed Cancer Innovations & Healthcare Index.
The fund includes:
- pharmaceutical giants Merck, with 4.8 % of the portfolio, Pfizer, 8.6 % and Abbott with 2.7 %,
- biotech leaders Chiron, accounting for 3.4% of the fund and Genentech with 9.4%, and
- medical equipment companies Beckman Coulter, with 1% of portfolio and Cytyc 1%